Protara Therapeutics Conference Call Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Industry**: Biotechnology, focusing on rare diseases and oncology - **Key Areas**: Non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations Core Points and Arguments Oncology Focus - Protara is developing therapies for non-muscle invasive bladder cancer, with two late-stage programs targeting BCG unresponsive and BCG naive patients [3][4] - The ADVANCED-2 study is a significant registrational study for BCG-unresponsive patients, with expected enrollment completion by the end of 2026 [4] - A randomized controlled trial (RCT) for BCG-naive patients has been approved by the FDA, marking a first in the NMIBC setting [4][11] Lymphatic Malformations Program - Protara's TAR 002 program targets macrocystic lymphatic malformations, showing a 100% clinical success rate at the eight-week evaluation point [7][14] - The company received breakthrough therapy designation and fast-track designation from the FDA, indicating a significant unmet need in this area [15][16] Market Opportunities - In NMIBC, 80% of patients are treated in community settings, where safety and tolerability are critical [9] - Protara's 002 therapy is positioned as a best-in-class option due to its safety profile and ease of administration [10] - The market opportunity for lymphatic malformations is estimated at around 1,000 patients annually in the U.S., with a focus on macrocystic cases [17][20] Clinical Data and Expectations - Upcoming data release in February for the ADVANCED-2 study is anticipated to show a complete response (CR) rate similar to previous findings of 72.4% at six months and 50% at twelve months [6][27] - The company aims to demonstrate that BCG-experienced and BCG-refractory patients respond similarly to TAR 002 [8] Competitive Landscape - Protara aims to position its therapies as alternatives to BCG, particularly for patients who cannot receive BCG [25] - The company is focused on generating level one evidence through its RCT, which will enhance its standing with payers and in treatment guidelines [12][13] Future Developments - Protara expects to begin receiving FDA approvals for its programs starting in 2027, with a robust pipeline of late-stage developments [22] - The IV Choline Chloride program is also in phase three, targeting a patient population of approximately 40,000 in the U.S. [21] Additional Important Content - The company emphasizes the importance of patient advocacy in raising awareness about new treatment options for lymphatic malformations [19] - Protara's leadership reflects on the journey of developing their portfolio, highlighting the progress made since going public in 2020 [34][35]

Group 1 - The call is focused on the updated interim results from the ongoing Phase II open-label ADVANCED-2 trial of TARA-002, which targets patients with non-muscle invasive bladder cancer [2] - Justine O'Malley, Senior Vice President of Investor Relations and Corporate Affairs, is leading the update call [2] - The conference is being recorded, and participants are reminded to disconnect if they have objections [1] Group 2 - Forward-looking statements will be made during the call, representing the company's views as of the current date [3] - Actual results may differ from these forward-looking statements due to various factors, as outlined in the Risk Factors section of the company's most recent annual report [4] - The company disclaims any obligation to update these forward-looking statements except as required by law [4]

Core Insights - Relmada Therapeutics announced positive 9-month follow-up safety and efficacy data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), achieving a 92% overall response rate [1][3] - The FDA provided feedback supporting two potential registrational trials for NDV-01, one for 2nd line refractory BCG-unresponsive NMIBC and another for intermediate-risk NMIBC [1][4] - The company plans to initiate Phase 3 pivotal programs for NDV-01 in the first half of 2026 [2][8] FDA Meeting Outcomes - The FDA confirmed that no additional non-clinical studies are required for the 505(b)(2) New Drug Application (NDA) [4] - A single-arm trial for high-grade, 2nd line BCG-unresponsive NMIBC patients is considered acceptable by the FDA [4] - A randomized controlled trial proposal for intermediate-risk NMIBC was also deemed generally acceptable [4] Clinical Results - The 9-month follow-up data showed a complete response rate of 92% (23/25) for all patients, with 84% (21/25) at 3 months and 87% (20/23) at 6 months [3][5] - In the BCG-unresponsive subpopulation, the complete response rates were 91% (10/11) at any time, 82% (9/11) at 3 months, and 78% (7/9) at 6 months [6][12] Safety Profile - No new safety signals were reported, with no patients experiencing Grade 3 treatment-related adverse events (AEs) [11] - Among 36 enrolled patients, 61% experienced treatment-related AEs, primarily transient dysuria (62%) [11] Product Overview - NDV-01 is a sustained-release formulation of gemcitabine and docetaxel designed for intravesical administration, allowing for gradual drug release over 10 days [8] - The product is convenient to administer in-office, requiring less than 10 minutes and no specialized equipment [8] Market Opportunity - NMIBC accounts for 75-80% of all bladder cancer cases, with a significant market opportunity due to high recurrence rates and limited treatment options [9]

Core Insights - Relmada Therapeutics reported a 91% overall response rate for NDV-01 in non-muscle invasive bladder cancer during a 6-month follow-up of a Phase 2 study, indicating strong efficacy and safety [1][3][4] - The company is preparing to initiate a Phase 3 registration trial for NDV-01 in the first half of 2026 and plans to start a Phase 2 study for sepranolone in Prader-Willi syndrome in the same timeframe [1][5] Clinical Results - The Phase 2 study of NDV-01 involved 29 patients, with a median age of 73 years. The study reported a complete response rate of 91% at any time point, 83% at 3 months, and 90% at 6 months [2][3] - No patients progressed to muscle invasive disease or underwent radical cystectomy, and no patients experienced Grade 3 treatment-related adverse events [3][4] Pipeline Developments - NDV-01 is a sustained-release formulation of gemcitabine and docetaxel, designed for intravesical administration, which enhances drug retention and minimizes systemic toxicity [10][12] - Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist targeting disorders linked to excess GABAergic activity, with plans for further clinical development [5][13] Financial Performance - For the second quarter ended June 30, 2025, Relmada reported a net loss of $9.9 million, or $0.30 per share, compared to a net loss of $17.8 million, or $0.59 per share, in the same period of the previous year [5][24] - Research and development expenses were $2.8 million for the quarter, down from $10.7 million in Q2 2024, primarily due to reduced trial costs [5][24] Market Opportunity - The U.S. market for high-grade/intermediate-grade non-muscle invasive bladder cancer is significant, with approximately 600,000 prevalent cases, highlighting the potential for NDV-01 as a frontline or salvage therapy [7][12] - Prader-Willi syndrome, targeted by sepranolone, has an estimated U.S. prevalence of 20,000 patients, representing an orphan disease market [7][14]